Navigation Links
Novel MR-guided radiation therapy platform highlighted at ASTRO meeting
Date:9/26/2013

ATLANTA, Sept. 26, 2013 /PRNewswire/ -- IMRIS Inc. (NASDAQ: IMRS; TSX: IM) and Varian Medical Systems (NYSE: VAR) today announced that data presented here earlier this week at the American Society for Radiation Oncology (ASTRO) Annual Meeting demonstrates the potential to direct state-of-the-art radiation treatments using diagnostic-quality MR images at each treatment session.

In a presentation to radiation oncology clinicians from around the globe, David Jaffray, PhD, a world-renowned radiation physicist at the Princess Margaret Cancer Centre and Director of the Techna Institute at the University Health Network (UHN) in Toronto, described a dedicated MR-guided radiation therapy suite that will allow a magnetic resonance (MR) scanner mounted on ceiling rails to perform MR-guided brachytherapy and external beam radiation delivery. Currently being installed at his institution, this unprecedented combination is a joint development combining IMRIS' MR imaging with Varian's TrueBeam® system for image-guided radiotherapy and radiosurgery.

"Tightly integrating MR imaging with treatment is expected to allow us to increase the accuracy of radiation delivery and pursue research in the emerging field of adaptive radiation therapy – the next level of image-guided radiotherapy that seeks to modify the treatment in response to changes in patient anatomy," said Jaffray. The team at the Princess Margaret has been performing research on the use of MR in radiation therapy as well as studying how the MR and radiation treatment technologies can be made compatible.

"While it is premature to speak to the clinical benefits of the development," he added, "the technical advantage of enhanced visualization of the tumor and normal tissues at the time of treatment opens many possibilities." The Princess Margaret team is planning to explore the system's use in the treatment of prostate, gynecological, and liver cancers, he said.

IMRIS and Varian are co-developing the MR-guided radiation therapy system that combines IMRIS's proprietary MR imaging technology with Varian's TrueBeam system to enable the use of MR imaging during radiotherapy treatments for cancer.  The two companies are collaborating with the team at The Princess Margaret Cancer Centre and UHN's Techna Institute in Toronto to develop the system, which is not cleared for sale in any jurisdiction at this time.

About IMRIS
IMRIS (NASDAQ: IMRS; TSX: IM) is a global leader in providing image guided therapy solutions through its VISIUS Surgical Theatre – a revolutionary, multifunctional surgical environment that provides unmatched intraoperative vision to clinicians to assist in decision making and enhance precision in treatment. The multi-room suites incorporate diagnostic quality high-field MR, CT and angio modalities accessed effortlessly in the operating room setting. VISIUS Surgical Theatres serve the neurosurgical, spinal, cardiovascular and cerebrovascular markets and have been selected by 54 leading medical institutions around the world.

For further information, please contact:
Kelly McNeill
Chief Financial Officer
IMRIS Inc.
Tel: 763-203-6304
Email: kmcneill@imris.com

About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes, digital detectors, and image processing workstations for X-ray imaging in medical, scientific, and industrial applications and also supplies high-energy X-ray devices for cargo screening and non-destructive testing applications. Varian Medical Systems employs approximately 6350 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com or follow us on Twitter.

Meryl Ginsberg
Director of Public Relations
Varian Medical Systems
Tel: 650-996-7487
Email: meryl.ginsberg@varian.com


'/>"/>
SOURCE Varian Medical Systems
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Prolong Pharmaceuticals Presents Novel Multi-Pronged Approach To Treating Sickle Cell Disease At The SCDAA Meeting
2. MabVax Therapeutics Receives $1,750,000 Small Business Innovation Research Contract Award From The National Cancer Institute To Support Development of Novel Pancreatic Cancer Diagnostic Imaging Agent
3. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
4. VisionCare Ophthalmic Technologies Secures Up To $15MM To Accelerate Growth Of Its Novel Treatment For Age-Related Macular Degeneration
5. Bayer and the Broad Institute Join Forces to Develop Novel Treatment Options in Cancer Therapy
6. NovelMed Awarded NIH Fast Track SBIR Grant for $1.43 Million to Advance Development of its Anti-Complement Antibody for Orphan Disease
7. Debiopharm Group and TCG Lifesciences Ltd. Enter into an Exclusive Research Agreement to Develop a Novel Class of Antibiotics, a New Strategic Therapeutic Area for Debiopharm
8. KemPharm Continues to Expand its Pain Therapy Pipeline with Discovery of KP606, a Novel Prodrug of Oxycodone
9. Among the Novel Oral Anticoagulants, Bayer/Janssens Xarelto is Positioned To Be the Sales-Leading Therapy for Venous Thromboembolism (VTE)
10. Novel LABA/LAMA Products Will Capture Greater Market Share than the LABA/ICS or LAMA Drug Classes by 2022
11. The Dyslipidemia Market Will Grow to $31 Billion in 2022, Driven by the Launch of Novel Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... South Korea , Oct. 4, 2017  South ... its next-generation CPR training aide "cprCUBE" on Kickstarter. The ... chest compression during cardiac arrests with better efficiency compared ... It also offers real-time feedback on efficacy of the ... The crowdfunding campaign has a goal to raise $5,000. ...
(Date:10/2/2017)... Lilly and Company (NYSE: LLY ) will ... 2017 on Tuesday, October 24, 2017. Lilly will also ... investment community and media to further detail the company,s ... at 9 a.m. Eastern time. Investors, media and the ... conference call through a link that will be posted ...
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and ... of published author, William Nowers. Captain Nowers and his wife, Millie, have six ... years in the Navy. Following his career as a naval aviator and carrier ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
Breaking Medicine News(10 mins):